Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateWages, Salaries and Other
Others
Ratios

Protalix BioTherapeutics (PLX) Non Operating Income (2016 - 2025)

Protalix BioTherapeutics (PLX) has 14 years of Non Operating Income data on record, last reported at $108000.0 in Q3 2025.

  • For Q3 2025, Non Operating Income rose 172.97% year-over-year to $108000.0; the TTM value through Sep 2025 reached $117000.0, up 117.18%, while the annual FY2024 figure was $237000.0, 112.51% up from the prior year.
  • Non Operating Income reached $108000.0 in Q3 2025 per PLX's latest filing, up from -$511000.0 in the prior quarter.
  • Across five years, Non Operating Income topped out at $413000.0 in Q1 2025 and bottomed at -$2.3 million in Q3 2021.
  • Average Non Operating Income over 5 years is -$534210.5, with a median of -$442000.0 recorded in 2022.
  • Peak YoY movement for Non Operating Income: crashed 507.37% in 2023, then soared 235.77% in 2025.
  • A 5-year view of Non Operating Income shows it stood at -$910000.0 in 2021, then grew by 21.43% to -$715000.0 in 2022, then decreased by 13.43% to -$811000.0 in 2023, then soared by 113.19% to $107000.0 in 2024, then increased by 0.93% to $108000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Non Operating Income were $108000.0 in Q3 2025, -$511000.0 in Q2 2025, and $413000.0 in Q1 2025.